Provided by Tiger Fintech (Singapore) Pte. Ltd.

DiaMedica Therapeutics Inc.

7.16
+1.0216.61%
Pre-market: 7.330.1700+2.37%04:28 EDT
Volume:2.13M
Turnover:14.92M
Market Cap:370.09M
PE:-10.37
High:7.49
Open:6.98
Low:6.57
Close:6.14
52wk High:7.49
52wk Low:3.19
Shares:51.69M
Float Shares:32.94M
Volume Ratio:4.94
T/O Rate:6.47%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.6903
EPS(LYR):-0.6050
ROE:-73.41%
ROA:-44.55%
PB:13.62
PE(LYR):-11.84

Loading ...

Company Profile

Company Name:
DiaMedica Therapeutics Inc.
Exchange:
NASDAQ
Establishment Date:
2000
Employees:
28
Office Location:
301 Carlson Parkway,Suite 210,Minneapolis,Minnesota,United States
Zip Code:
55305
Fax:
- -
Introduction:
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase 2/3 REMEDY2 trials for the treatment of patients with acute ischemic stroke. It is also developing DM300 that is in pre-clinical stage for the treatment of inflammatory diseases. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

Directors

Name
Position
James Parsons
Chairman of the Board
Rick Pauls
Director, President and Chief Executive Officer
Charles P. Semba
Independent Director
Michael Giuffre
Independent Director
Richard E. Kuntz
Independent Director
Tanya N. Lewis
Independent Director
Daniel J. O'Connor
Director

Shareholders

Name
Position
Rick Pauls
Director, President and Chief Executive Officer
Scott Kellen
Chief Financial Officer, Principal Accounting Officer and Secretary
David J. Wambeke
Chief Business Officer
Julie Krop
Chief Medical Officer